Drugs / NNC0165-1562
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03574584 | Jun 2018 → Jul 2019 | metabolic disease, obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02568306 | Oct 2015 → Feb 2017 | metabolic disease, obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC0165-1562 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03574584 ↗ |
| Route | Subcutaneous | “Administered subcutaneously (s.c., under the skin)” NCT02568306 ↗ |